%0 Journal Article
%T 抗PD-1/PD-L1治疗在肿瘤治疗中的研究进展
%A 景楚瑜(综述)
%A 张博恒
%A △(审校)
%J 复旦大学（医学报）
%D 2016
%X </br>Programmed death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) are a pair of immune co-inhibitory molecules. Agents targeting the PD-1/PD-L1 pathway reactivated the autologous anti-tumor immune response and yielded strong and prolonged therapeutic effect in various cancer types. However, how to predict whether an individual is sensitive to the anti-PD-1/PD-L1 therapy and how to achieve higher response rates with combined therapies require further investigation. This review summarized the biological mechanism of the PD-1/PD-L1 pathway, the latest results of anti-PD-1/PD-L1 therapy, furthermore probed into potential biomarkers that predict the therapeutic effects and advancements in combined immune therapy.
%K &lt
%K /br&gt
%K tumor immunotherapy PD-1 PD-L1
%U http://jms.fudan.edu.cn/CN/abstract/abstract1339.shtml